Regulatory approval

Published by the European Medicines Agency. Approved

OPDIVO in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by OPDIVO as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression >= 1%.

This is written in the approval document.

Citation

Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Docetaxel, Nivolumab

Contributions

Date Contributor Description
2025-09-04 Van Allen lab On 2025-06-02, the EMA published an EPAR - Assessment report - Variation for Opdivo (nivolumab) for that added an extension indication to nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment, followed by nivolumab as monotherapy as adjuvant treatment, of patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%.
2025-05-15 European Medicines Agency Indication received approval from the European Commission.